Targeted Cancer Therapies in 2025: How Your DNA Can Personalise Your Treatment

Cancer treatment has evolved dramatically in recent years. The traditional “one-size-fits-all” approach is giving way to a highly personalised method—one driven not only by DNA mutations but also by epigenetic changes, gene expression patterns (transcriptomics), and protein-level dynamics (proteomics). In 2025, Neeli Genetics is at the forefront of this transformation, helping patients and doctors tailor therapies with unmatched precision.

What Is Personalised Cancer Therapy and Why Does It Matter?

Personalised cancer therapy focuses on identifying the unique biological characteristics of a patient’s tumour. This goes beyond just spotting mutations. Today’s advanced diagnostics examine:

Genetic Mutations – Abnormalities in DNA that drive cancer growth.

Epigenetics – Changes in gene activity without alterations in the DNA sequence, such as DNA methylation and histone modifications, which can silence tumor-suppressor genes.

Transcriptomics – Analysis of RNA expression levels to see which genes are active in the tumour and influencing its behaviour.

Proteomics – Profiling the proteins produced by cancer cells, including signalling molecules, receptors, and enzymes that drive proliferation and resistance.

By combining insights from all four layers, oncologists can create precision treatment strategies that are significantly more effective and less toxic than standard chemotherapy.

Understanding Targeted Therapy: A Multi-Layered Approach

Targeted therapy refers to drugs or interventions designed to interfere with specific molecular targets identified through deep biological profiling of the tumour. These therapies now increasingly incorporate data from:

DNA Sequencing (for mutations like EGFR, BRCA, KRAS)

Methylation Panels (for epigenetic silencing of tumour suppressor genes)

RNA Sequencing (to assess active cancer-driving pathways)

Proteomic Arrays (to find overexpressed cancer proteins or immune evasion markers)

Unlike traditional chemotherapy, which affects both cancerous and healthy cells, this integrated approach enables treatment to focus only on what drives the cancer, minimising collateral damage and improving outcomes.

Top 5 Cancer Types Benefiting from Comprehensive Genetic-Based Treatments

These groundbreaking comprehensive genetic-based treatments have dramatically improved the prognosis for patients with various cancer types. By targeting specific genetic mutations, doctors can offer more precise and effective therapies that serve each patient’s unique genetic profile. Here are the top 5 cancer types that are benefiting most from these advancements in personalised cancer treatment.

1. Breast Cancer: Beyond HER2—Epigenetic & Transcriptomic Insights

In addition to HER2-targeted drugs like trastuzumab, many breast cancers involve epigenetic silencing of BRCA1 or hormone receptor modulation revealed through transcriptomic profiling. Neeli Genetics offers full-spectrum analysis to identify these factors and design precision hormone therapies or epigenetic modulators.

2. Lung Cancer: EGFR Mutations, PD-L1 Proteomics & Immune Activation

NSCLC patients often carry EGFR, ALK, or ROS1 mutations, but many also benefit from proteomic profiling of PD-L1 or transcriptomic markers predicting immunotherapy response. Neeli Genetics provides this comprehensive view to guide both targeted therapy and immune checkpoint inhibitors.

3. Colorectal Cancer: KRAS, MSI Status, and Methylation Patterns

Colorectal cancer management now involves identifying KRAS/NRAS mutations and microsatellite instability (MSI). However, methylation of MLH1 and other mismatch repair genes is also critical for selecting immunotherapies. Neeli Genetics combines all these insights in one test panel.

4. Leukaemia & Lymphoma: CAR-T + RNA/Protein Biomarkers

Beyond CAR-T therapy, transcriptomic profiling helps predict resistance mechanisms and relapse potential. Proteomic markers like CD19 and CD22 determine eligibility for cell therapies. Neeli Genetics supports these patients with real-time immune and molecular monitoring.

5. Ovarian Cancer: BRCA Mutations, HRD, and Proteomic Signatures

PARP inhibitors work best in patients with BRCA1/2 mutations or homologous recombination deficiency (HRD). Proteomic biomarkers, such as elevated VEGF or FOLR1, can guide anti-angiogenic and immunomodulatory strategies. Neeli Genetics’ panel ensures every angle is covered.

Benefits of Full Spectrum Genetic Testing for Cancer Patients

Genetic testing provides several key benefits to cancer patients:

Faster & More Accurate Diagnosis –

Multilayer testing (DNA + RNA + epigenetics + proteomics) speeds up the identification of cancer drivers and helps avoid trial-and-error treatments.

Fewer Side Effects –

With therapies precisely targeted to active cancer pathways, damage to healthy tissues is minimised, improving patient quality of life.

Higher Success Rates –

Integrative analysis dramatically increases the chances of remission or durable response, especially when resistance mutations or pathway redundancies are identified early.

How to Access Genetic and Multi-omic Testing in 2025

In 2025, genetic testing for cancer treatment has become more accessible than ever. Here’s what you need to know about the process:

Process –

A simple blood sample or tumour biopsy can be used to extract DNA, RNA, proteins, and methylation data. Within 10–14 days, you will receive a comprehensive molecular report with expert interpretation and therapy recommendations.

Cost & Availability –

Thanks to cutting-edge automation, these tests are now more affordable in India than ever. Neeli Genetics offers flexible panels based on cancer type, clinical urgency, and therapeutic need.

Where to Get Tested –

Testing is available through major hospitals, oncology clinics, and directly through Neeli Genetics’ patient portals or authorised partners.

Final Thoughts: The Future of Cancer Treatment is Personalised & Already Here

Cancer is no longer a singular disease with a standard solution. Every tumour carries its biological fingerprint, composed of genetic mutations, epigenetic shifts, RNA activity, and protein-level signalling. The key to effective treatment in 2025 lies in decoding this complexity and turning it into actionable insights. This not only improves treatment accuracy and reduces side effects but also opens the door to options that may have previously been overlooked. The future of cancer care is already here, and it’s built on data, science and a commitment to personalised healing.